DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 8,080,553 B2 Keith Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 8,080,553 B2 Keith Et Al USO08080553B2 (12) United States Patent (10) Patent No.: US 8,080,553 B2 Keith et al. (45) Date of Patent: Dec. 20, 2011 (54) METHODS AND REAGENTS FOR THE 35E, A 12 E. auffmanA. et al.al TREATMENT OF IMMUNON FLAMMATORY 5,326,764 A 7, 1994 Milstone et al. DSORDERS 5,428,040 A 6/1995 Magolda et al. 5,468,729 A 11/1995 Chretien et al. (75) Inventors: Curtis Keith, Boston, MA (US); Alexis 5,639,759 A 6/1997 Magolda et al. 5,668,116 A 9, 1997 Cullis-Hill et al. S.A.Immermann, NA's, SomerV11 MA SSan. le. (US); 5,756,5535,728,712 A 3/19985/1998 IguchiMontana et al.et al. Edward Roydon Jost-Price, West 5,762.918 A 6/1998 Thorpe Roxbury, MA (US); Palaniyandi 3.3 A s 3. als. 1 Manivasakam, West Roxbury, MA 5,874.441 A 2/1999 Magoldaarvey et et al. al. (US); Nicole Hurst, Boston, MA (US); 5,958,926. A 9/1999 Garvey et al. Michael A. Foley, Chestnut Hill, MA 6,010,716 A 1/2000 Saunal et al. (US); Michael S. Slavonic, Quincy, MA 8.83, A 38 S.ekut et al.al (US);S. ENBenjamin suit A. Auspitz, SEEA. Cambridge, E. 6,110,9106,071,514. A 8/20006/2000 GrinnellMagolda etet al.al. MA (US) 6,133,272 A 10/2000 Garvey et al. 6,172,060 B1 1/2001 Garvey et al. (73) Assignee: Zalicus Inc., Cambridge, MA (US) 6,172,068 B1 1/2001 Garvey et al. 6,177,428 B1 1/2001 Garvey et al. (*)c Notice:- r Subject to any disclaimer, the term of this 6, 197,782197,778 B1 3/2001 Garvey et al. patent is extended or adjusted under 35 6.211179 B1 4/2001 Garvey et al. U.S.C. 154(b) by 1504 days. 6,221,881 B1 4/2001 Garvey et al. 6,232,321 B1 5/2001 Garvey et al. (21) Appl. No.: 11/517,593 6,265,427 B1 7/2001 Camden 6,316,457 B1 1 1/2001 Garvey et al. 1-1. 6,331.543 B1 12/2001 Garvey et al. (22) Filed: Sep. 7, 2006 6,337,325 B1 1/2002 Schonharting et al. O O 6,372.254 B1 4/2002 Ting et al. (65) Prior Publication Data 6,383,471 B1 5/2002 Chen et al. 6,403,571 B2 6/2002 Gould et al. US 2007/OO 105O2A1 Jan. 11, 2007 6,462,044 B2 10/2002 Garvey et al. O O 6,515,010 B1 2/2003 Franchini et al. Related U.S. Application Data 6,602,521 B1 8/2003 Ting et al. 6,677,326 B2 1/2004 Bardslev et al. (63) Continuation of application No. 10/966.228, filed on 6,730,321 B2 5, 2004 is: al Oct. 15, 2004, now abandoned. 7,253,155 B2 8, 2007 Keith et al. (60) Provisional application No. 60/512,415, filed on Oct. (Continued) 15, 2003. FOREIGN PATENT DOCUMENTS (51) Int. Cl. CN 1246335 A 3, 2000 AOIN 43/54 (2006.01) (Continued) AOIN 43/90 (2006.01) A 6LX3/57 (2006.01) A 6LX3/59 (2006.01) OTHER PUBLICATIONS CO7D 239/42 (2006.01) Boileau et al. Arthritis & Rheumatism, 2002, vol. 46, No. 10, pp. CO7D40 L/04 (2006.01) 2637-2647.* (52) U.S. Cl. ..................................... 514/258.1; 514/256 (58) Field of Classification Search ............... 514/258.1, (Continued)Continued 514/256 See application file for complete search history. Primary Examiner — Sreeni Padmanabhan Assistant Examiner — Samira Jean-Louis (56) References Cited (74) Attorney, Agent, or Firm — Clark & Elbing LLP U.S. PATENT DOCUMENTS 3,031,450 A 4, 1962 Fischer et al. (57) ABSTRACT 3,934,036 A 1/1976 Irikura 3,944,577 A 3, 1976 Laurent et al. The invention features a method for treating a patient diag 4,034,087 A 7, 1977 Voorhees nosed with, or at risk of developing, an immunoinflammatory 4,107,306 A 8, 1978 Voorhees disorder by administering to the patient a tetra-substituted 4,254,122 A 3/1981 Brown .......................... 514,245 pyrimidopyrimidine, either alone or in combination with one 4,367,217 A 1/1983 Gruber et al. 4,499,093 A 2f1985 Galabov et al. or more additional agents. The invention also features a com 4,554,271 A 1 1/1985 Braughler et al. position containing a tetra-substituted pyrimidopyrimidine in 4,685,911 A 8, 1987 Konno et al. combination with one or more additional agents. 4,879,119 A 11, 1989 Konno et al. 5,051.262 A 9, 1991 Panoz et al. 5,242.921 A 9, 1993 Milstone et al. 22 Claims, No Drawings US 8,080,553 B2 Page 2 U.S. PATENT DOCUMENTS Baxter et al., “Mechanism of Glucocorticoid Action: General Fea 2001/0007083 A1 7/2001 Roorda et al. tures, with Reference to Steroid-Mediated Immunosuppression.” 2001 OO16604 A1 8, 2001 Yu et al. Transplant. Proc. 7:55-65 (1975). 2002fOO19405 A1 2/2002 Garvey et al. Berger et al., “Comparative Carcinogenic Activity of Prednimustine, 2003,0003151 A1 1/2003 Chopra Chlorambucil, Prednisolone and Chlorambucil Plus Prednisolone in 2003, OO23087 A1 1/2003 Garvey et al. Sprague-Dawley Rats.” Arch. Geschwulstforsch 55:429-442 (1985). 2003, OO691.69 A1 4/2003 Macor et al. 2003/0077229 A1 4/2003 Dugger Berger et al., “Long-Term Toxicology Effects of Prednimustine in 2003/0078246 A1* 4/2003 Sackeyfio et al. ............. 514,171 Comparison with Chlorambucil, Prednisolone, and Chlorambucil 2003/0203028 A1 10/2003 Ting et al. Plus Prednisolone in Sprague-Dawley Rats.” Semin. Oncol. 13:8-13 2004/0087486 A1 5, 2004 Hanson (1986). 2004/OO87591 A1 5/2004 Garvey et al. Berkow et al., “The Merck Manual.” fifteenth edition, pp. 797-807 2004/0180812 A1 9, 2004 Dicker et al. (1987). 2005, OO19393 A1 1/2005 Augsburger et al. Berkow et al., “Merck Manual of Medical Information.' Home edi 2005/0O25713 A1 2/2005 Dugger 2005, 0037074 A1 2/2005 ROSS et al. tion, pp. 248-255 (1997). 2005, OO58688 A1 3/2005 Boerger et al. Brunette et al., "Long-term Immunosuppressive Treatment of a Child 2005, 011916.0 A1 6, 2005 Keith et al. with Takayasu's Arteritis and High IgE Immunoglobulins.” Pediatr. 2006/0234991 A1 10, 2006 Keith et al. Nephrol. 10:67-69 (1996). 2007/00105O2 A1 1/2007 Keith et al. Bruserud, “Dipyridamol Inhibits Activation of Human T Lympho 2007,0196491 A1 8, 2007 Venkatesh cytes. In Vitro.” Clin. Immunol. Immunopathol. 42:102-109 (1987). 2007/0213296 A1 9/2007 Zhang Casset al., “A Comparison of the Abilities of Nitrobenzylthioinosine, 2007/0213308 A1 9, 2007 Lessem et al. Dilazep, and Dipyridamole to Protect Human Hematopoietic Cells 2009.0075955 A1 3, 2009 Padval From 7-Deazaadenosine (Tubercidin).” Cancer Res. 52:5879-5886 FOREIGN PATENT DOCUMENTS (1992). EP O3O3 713 B1 5, 1993 Cazenave et al., “Inhibition of Platelet Adherence to a Collagen EP O 543 653 A1 5, 1993 coated Surface by Nonsteroidal Anti-inflammatory Drugs, Pyrimido EP 1 O93814 A1 4/2001 pyrimidine and Tricyclic Compounds, and Lidocaine” J. Lab. Clin. GB 2 292 O79 2, 1996 Med. 83:797-806 (1974). WO WO 89.10.122 11, 1989 Conway et al., “Inhibition of Cartilage and Bone Destruction in WO WO92, 16226 10, 1992 Adjuvant Arthritis in the Rat by a Matrix Metalloproteinase Inhibi WO WO98, 19672 5, 1998 tor.” J. Exp. Med. 182:449-457 (1995). WO WO98,55142 12/1998 Curtin et al., “Potentiation of the Cytotoxicity of Thymidylate WO WO99, 16417 4f1999 Synthase (TS) Inhibitors by Dipyridamole Analogues with Reduced WO WO99/62537 12/1999 O-acid Glycoprotein Binding Br. J. Cancer 80:1738-1746 (1999). WO WOOOf 12076 3, 2000 Eigler et al., “Endogenous Adenosine Curtails Lipopolysaccharide WO WOOOf 12497 3, 2000 WO WOOO,594.75 10, 2000 Stimulated Tumour Necrosis Factor Synthesis.” Scan J. Immunol. WO WOO1? 47572 A2 T 2001 45:132-139 (1997). WO WOO1, 54.679 A2 8, 2001 Feldmann et al., “Anti-TNFO. Therapy of Rheumatoid Arthritis: What WO WOO1? 68056 9, 2001 Have We Learned?” Annu. Rev. Immunol. 19:163-196 (2001). WO WO O2/22 127 A1 3, 2002 Goh et al., “Nitrobenzylthioinosine-binding Protein Overexpression WO WO O2/O69905 9, 2002 in Human Breast, Liver, Stomach and Colorectal Tumour Tissues.” WO WO O2/O85304 A2 10, 2002 Anticancer Res. 15:2575-2580 (1995). WO WO O2/O94227 A1 11, 2002 Griffon-Etienne et al., “Taxane-induced Apoptosis Decompresses WO WOO3,OO6026 1, 2003 Blood Vessels and Lowers Interstitial Fluid Pressure in Solid Tumors: WO WOO3,O3O823 4/2003 Clinical Implications.” Cancer Res. 59: 3776-3782 (1999). WO WO 03/043603 A1 5, 2003 Harada et al., “Renal Amyloidosis Associated with Crescentic WO WO 2004/O19909 A2 3, 2004 WO WO 2004/069254 A2 8, 2004 Glomerulonephritis' Am. J. Nephrol. 4:52-55 (1984). WO WO 2005/020933 A2 3, 2005 Haskö et al., “Adenosine Inhibits IL-12 and TNF-60 Production Via WO WO 2005/03O132 4/2005 Adenosine A Receptor-Dependent and Independent Mechanisms.” WO WO 2005/0372O3 4/2005 FASEB.J. 14:2065-2074 (2000). WO WO 2007/089617 8, 2007 Iijima et al., “Multiple Combined Therapy for Severe Henoch WO WO 2007/103373 9, 2007 Schönlein Nephritis in Children.” Pediatr Nephrol. 12:244-248 OTHER PUBLICATIONS (1998). Konstantinov et al., “Interferon Response to Dipyridamole in Lupus Forrest CMetal. "Adenosine and Cytokine Levels Following Treat Erythematosus Patients” Br: J. Dermatol. 121:59-63 (1989). ment of Rheumatoid Arthritis with Dipyridamole'.
Load more

Recommended publications
  • This Fact Sheet Provides Information to Patients with Eczema and Their Carers. About Topical Corticosteroids How to Apply Topic
    This fact sheet provides information to patients with eczema and their carers. About topical corticosteroids You or your child’s doctor has prescribed a topical corticosteroid for the treatment of eczema. For treating eczema, corticosteroids are usually prepared in a cream or ointment and are applied topically (directly onto the skin). Topical corticosteroids work by reducing inflammation and helping to control an over-reactive response of the immune system at the site of eczema. They also tighten blood vessels, making less blood flow to the surface of the skin. Together, these effects help to manage the symptoms of eczema. There is a range of steroids that can be used to treat eczema, each with different strengths (potencies). On the next page, the potencies of some common steroids are shown, as well as the concentration that they are usually used in cream or ointment preparations. Using a moisturiser along with a steroid cream does not reduce the effect of the steroid. There are many misconceptions about the side effects of topical corticosteroids. However these treatments are very safe and patients are encouraged to follow the treatment regimen as advised by their doctor. How to apply topical corticosteroids How often should I apply? How much should I apply? Apply 1–2 times each day to the affected area Enough cream should be used so that the of skin according to your doctor’s instructions. entire affected area is covered. The cream can then be rubbed or massaged into the Once the steroid cream has been applied, inflamed skin. moisturisers can be used straight away if needed.
    [Show full text]
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • Adrenal Disorders
    Adrenal Disorders Dual-release Hydrocortisone in Addison’s Disease— A Review of the Literature Roberta Giordano, MD,1 Federica Guaraldi, MD,2 Rita Berardelli, MD,2 Ioannis Karamouzis, MD,2 Valentina D’Angelo, MD,2 Clizia Zichi, MD,2 Silvia Grottoli, MD,2 Ezio Ghigo, PhD2 and Emanuela Arvat, PhD3 1. Department of Clinical and Biological Sciences; 2. Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences; 3. Division of Oncological Endocrinology, Department of Medical Sciences, University of Turin, Turin, Italy Abstract In patients with adrenal insufficiency, glucocorticoids (GCs) are insufficiently secreted and GC replacement is essential for health and, indeed, life. Despite GC-replacement therapy, patients with adrenal insufficiency have a greater cardiovascular risk than the general population, and suffer from impaired health-related quality of life. Although the aim of the replacement GC therapy is to reproduce as much as possible the physiologic pattern of cortisol secretion by the normal adrenal gland, the pharmacokinetics of available oral immediate-release hydrocortisone or cortisone make it impossible to fully mimic the cortisol rhythm. Therefore, there is an unmet clinical need for the development of novel pharmaceutical preparations of hydrocortisone, in order to guarantee a more physiologic serum cortisol concentration time-profile, and to improve the long-term outcome in patients under GC substitution therapy. Keywords Addison’s disease, glucocorticoids, hydrocortisone, Plenadren®, limits, advantages Disclosure: The authors have no conflicts of interest to declare. Received: June 28, 2013 Accepted: August 9, 2013 Citation: US Endocrinology 2013;9(2):177–80 DOI: 10.17925/USE.2013.09.02.177 Correspondence: Roberta Giordano, MD, Division of Endocrinology, Diabetology and Metabolism, Department of Medical Sciences, Azienda Ospedaliera Città della Salute e della Scienza di Torino, C so Dogliotti 14, 10126 Turin, Italy.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Frequently Asked Questions for Addison Patients
    FREQUENTLY ASKED QUESTIONS FOR ADDISON PATIENTS TABLE OF CONTENT (Place your cursor over the subject line, hold down the Control Button and Click your mouse. To get back to the Table of Content, hold down the Control Button and press the Home key) ADDISONIAN CRISIS / EMERGENCY ADDISONS AND OTHER DISORDERS ADDISONS AND OTHER MEDICATIONS ADRENALINE BLOOD PRESSURE COMMON COLD/FLU/OTHER ILLNESS CORTISOL DAY CURVE CORTISOL MEDICATION CRAMPS DIABETES DIAGNOSING ADDISONS EXERCISE / SPORTS FATIGUE FLORINEF / SALT / SODIUM HERBAL / VITAMIN SUPPLEMENTS HYPERPIGMENTATION IMMUNIZATION MENOPAUSE, PREGNANCY, HORMONE REPLACEMENT, BIRTH CONTROL, HYSTERECTOMY MISCELLANEOUS OSTEOPOROSIS SECONDARY ADDISON’S SHIFT WORK SLEEP 1 STRESS DOSING SURGICAL, MEDICAL, DENTAL PROCEDURES THYROID TRAVEL WEIGHT GAIN 2 ADDISONIAN CRISIS / EMERGENCY How do you know when to call an ambulance? If you are careful, you should not have to call an ambulance. If someone with adrenal insufficiency has gastrointestinal problems and is unable to keep down their cortisol or other glucocorticoid for more than 24 hrs, they should be taken to an emergency department so they can be given intravenous solucortef and saline. It is not appropriate to wait until they are so ill that they cannot be taken to the hospital by a family member. If the individual is unable to retain anything by mouth and is very ill, or if they have had a sudden stress such as a fall or an infection, then it would be necessary for them to go by ambulance as soon as possible. It is important that you should have an emergency kit at home and that someone in the household knows how to use it.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Keloids and Hypertrophic Scars Can Now Be Cured Completely: Recent Progress in Our Understanding of the Pathogenesis of Keloids and Hypertrophic Scars and the Most
    ―Review― Keloids and Hypertrophic Scars Can Now Be Cured Completely: Recent Progress in Our Understanding of the Pathogenesis of Keloids and Hypertrophic Scars and the Most Promising Current Therapeutic Strategy Rei Ogawa1, Satoshi Akaishi1, Shigehiko Kuribayashi2 and Tsuguhiro Miyashita2 1Department of Plastic, Reconstructive and Aesthetic Surgery, Nippon Medical School, Tokyo, Japan 2Department of Radiation Oncology, Nippon Medical School, Tokyo, Japan Keloids and hypertrophic scars are fibroproliferative disorders of the skin that are caused by abnormal healing of injured or irritated skin. It is possible that they are both manifestations of the same fibropro- liferative skin disorder and just differ in terms of the intensity and duration of inflammation. These fea- tures may in turn be influenced by genetic, systemic, and local risk factors. Genetic factors may include single nucleotide polymorphisms, while systemic factors may include hypertension, pregnancy, hor- mones, and cytokines. The most important local factor is tension on the scar. Over the past 10 years, our understanding of the pathogenesis of keloids and hypertrophic scars has improved markedly. As a result, these previously intractable scars are now regarded as being treatable. There are many therapeu- tic options, including surgery, radiation, corticosteroids, 5-fluorouracil, cryotherapy, laser therapy, anti- allergy agents, anti-inflammatory agents, bleaching creams and make-up therapies. However, at present, we believe that the following combination of three therapies most reliably achieves a complete cure: surgery, followed by radiation and the use of steroid tape/plaster. (J Nippon Med Sch 2016; 83: 46―53) Key words: keloid, hypertrophic scar, radiation, steroid, steroid tape Introduction that more superficial damage would not elicit keloids Keloids and hypertrophic scars are fibroproliferative dis- and hypertrophic scars.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • A New Robust Technique for Testing of Glucocorticosteroids in Dogs and Horses Terry E
    Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 2007 A new robust technique for testing of glucocorticosteroids in dogs and horses Terry E. Webster Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Veterinary Toxicology and Pharmacology Commons Recommended Citation Webster, Terry E., "A new robust technique for testing of glucocorticosteroids in dogs and horses" (2007). Retrospective Theses and Dissertations. 15029. https://lib.dr.iastate.edu/rtd/15029 This Thesis is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. A new robust technique for testing of glucocorticosteroids in dogs and horses by Terry E. Webster A thesis submitted to the graduate faculty in partial fulfillment of the requirements for the degree of MASTER OF SCIENCE Major: Toxicology Program o f Study Committee: Walter G. Hyde, Major Professor Steve Ensley Thomas Isenhart Iowa State University Ames, Iowa 2007 Copyright © Terry Edward Webster, 2007. All rights reserved UMI Number: 1446027 Copyright 2007 by Webster, Terry E. All rights reserved. UMI Microform 1446027 Copyright 2007 by ProQuest Information and Learning Company. All rights reserved. This microform edition is protected against unauthorized copying under Title 17, United States Code. ProQuest Information and Learning Company 300 North Zeeb Road P.O. Box 1346 Ann Arbor, MI 48106-1346 ii DEDICATION I want to dedicate this project to my wife, Jackie, and my children, Shauna, Luke and Jake for their patience and understanding without which this project would not have been possible.
    [Show full text]
  • Steroid Use in Prednisone Allergy Abby Shuck, Pharmd Candidate
    Steroid Use in Prednisone Allergy Abby Shuck, PharmD candidate 2015 University of Findlay If a patient has an allergy to prednisone and methylprednisolone, what (if any) other corticosteroid can the patient use to avoid an allergic reaction? Corticosteroids very rarely cause allergic reactions in patients that receive them. Since corticosteroids are typically used to treat severe allergic reactions and anaphylaxis, it seems unlikely that these drugs could actually induce an allergic reaction of their own. However, between 0.5-5% of people have reported any sort of reaction to a corticosteroid that they have received.1 Corticosteroids can cause anything from minor skin irritations to full blown anaphylactic shock. Worsening of allergic symptoms during corticosteroid treatment may not always mean that the patient has failed treatment, although it may appear to be so.2,3 There are essentially four classes of corticosteroids: Class A, hydrocortisone-type, Class B, triamcinolone acetonide type, Class C, betamethasone type, and Class D, hydrocortisone-17-butyrate and clobetasone-17-butyrate type. Major* corticosteroids in Class A include cortisone, hydrocortisone, methylprednisolone, prednisolone, and prednisone. Major* corticosteroids in Class B include budesonide, fluocinolone, and triamcinolone. Major* corticosteroids in Class C include beclomethasone and dexamethasone. Finally, major* corticosteroids in Class D include betamethasone, fluticasone, and mometasone.4,5 Class D was later subdivided into Class D1 and D2 depending on the presence or 5,6 absence of a C16 methyl substitution and/or halogenation on C9 of the steroid B-ring. It is often hard to determine what exactly a patient is allergic to if they experience a reaction to a corticosteroid.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]